- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Senate Passes Bill To Accelerate Medical Device Approvals
Fortune reported that a Senate committee has approved a group of bills that aim to speed up medical device approvals by the Food and Drug Administration. The move is intended to increase funding for medical research and help move new products through the regulatory process quicker.
Fortune reported that a Senate committee has approved a group of bills that aim to speed up medical device approvals by the Food and Drug Administration. The move is intended to increase funding for medical research and help move new products through the regulatory process quicker.
According to the report:
The measures were approved Wednesday with bipartisan support across most of the issues, reported The Wall Street Journal. Democrats got on board after heavy negotiations that led to a budgetary boost for medical research at the National Institutes of health, as well as a simplified approval process for “breakthrough” products, and Republicans agreed to narrow the number of devices under that designation.
Diana Zuckerman, president of the National Center for Health Research in Washington stated:
We are concerned that the focus of these bills is on getting medical products to market more quickly, instead of making sure they are safe and effective.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.